Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia

Ashwini Mallappa, Aikaterini A. Nella, Ninet Sinaii, Hamsini Rao, Verena Gounden, Ashley F. Perritt, Parag Kumar, Alexander Ling, Chia Ying Liu, Steven J. Soldin, Deborah P. Merke

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: In a phase 2 short-term (6 months) study of patients with congenital adrenal hyperplasia (CAH), continuous subcutaneous hydrocortisone infusion (CSHI) was found to be a safe, effective and well-tolerated method of replacing cortisol with improved disease and patient-related outcomes. Objective: To evaluate the safety and efficacy of long-term CSHI. Design: Single-centre, open-label, phase 2 extension study. Patients: Five adults with classic CAH. Measurements: Biomarkers of disease control, metabolic indices and health-related quality-of-life (HRQoL) estimates. Results: Six of eight patients chose to continue on long-term CSHI therapy. Compared to baseline, eighteen months of CSHI resulted in decreased (P = 0.043) 0700-hour ACTH, 17-hydroxyprogesterone, androstenedione and progesterone; increased whole-body lean mass (P = 0.024); and improved HRQoL, especially symptoms of adrenal insufficiency (P = 0.003). Findings at six and eighteen months did not differ, and improvements achieved in androgen control, lean body mass and HRQoL after 6 months of CSHI were maintained at eighteen months. The hydrocortisone dose appeared to decrease with time [6 vs 18 months: 38.3 ± 8.8 vs 33.6 ± 12.2 mg/day (P = 0.062)], especially in women receiving oral contraceptives. Reduction of testicular adrenal rest and adrenal size observed at 6 months remained stable. In one patient, an adrenal adenoma continually decreased over time. Subjective improvement in hirsutism was reported. Conclusions: Long-term use of CSHI is a safe and well-tolerated treatment option in a select set of adults with classic CAH. Improvements observed short term in disease control and subjective health status continued long term.

Original languageEnglish (US)
JournalClinical Endocrinology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Subcutaneous Infusions
Congenital Adrenal Hyperplasia
Hydrocortisone
Quality of Life
Therapeutics
17-alpha-Hydroxyprogesterone
Hirsutism
Adrenal Insufficiency
Diagnostic Self Evaluation
Androstenedione
Metabolic Diseases
Oral Contraceptives
Adenoma
Adrenocorticotropic Hormone
Androgens
Health Status
Progesterone
Biomarkers
Safety

Keywords

  • circadian
  • congenital adrenal hyperplasia
  • continuous subcutaneous hydrocortisone infusion

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Mallappa, A., Nella, A. A., Sinaii, N., Rao, H., Gounden, V., Perritt, A. F., ... Merke, D. P. (Accepted/In press). Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia. Clinical Endocrinology. https://doi.org/10.1111/cen.13813

Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia. / Mallappa, Ashwini; Nella, Aikaterini A.; Sinaii, Ninet; Rao, Hamsini; Gounden, Verena; Perritt, Ashley F.; Kumar, Parag; Ling, Alexander; Liu, Chia Ying; Soldin, Steven J.; Merke, Deborah P.

In: Clinical Endocrinology, 01.01.2018.

Research output: Contribution to journalArticle

Mallappa, A, Nella, AA, Sinaii, N, Rao, H, Gounden, V, Perritt, AF, Kumar, P, Ling, A, Liu, CY, Soldin, SJ & Merke, DP 2018, 'Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia', Clinical Endocrinology. https://doi.org/10.1111/cen.13813
Mallappa, Ashwini ; Nella, Aikaterini A. ; Sinaii, Ninet ; Rao, Hamsini ; Gounden, Verena ; Perritt, Ashley F. ; Kumar, Parag ; Ling, Alexander ; Liu, Chia Ying ; Soldin, Steven J. ; Merke, Deborah P. / Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia. In: Clinical Endocrinology. 2018.
@article{2cc2d5fb1c5c44a2811d247f1a7c6ee3,
title = "Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia",
abstract = "Background: In a phase 2 short-term (6 months) study of patients with congenital adrenal hyperplasia (CAH), continuous subcutaneous hydrocortisone infusion (CSHI) was found to be a safe, effective and well-tolerated method of replacing cortisol with improved disease and patient-related outcomes. Objective: To evaluate the safety and efficacy of long-term CSHI. Design: Single-centre, open-label, phase 2 extension study. Patients: Five adults with classic CAH. Measurements: Biomarkers of disease control, metabolic indices and health-related quality-of-life (HRQoL) estimates. Results: Six of eight patients chose to continue on long-term CSHI therapy. Compared to baseline, eighteen months of CSHI resulted in decreased (P = 0.043) 0700-hour ACTH, 17-hydroxyprogesterone, androstenedione and progesterone; increased whole-body lean mass (P = 0.024); and improved HRQoL, especially symptoms of adrenal insufficiency (P = 0.003). Findings at six and eighteen months did not differ, and improvements achieved in androgen control, lean body mass and HRQoL after 6 months of CSHI were maintained at eighteen months. The hydrocortisone dose appeared to decrease with time [6 vs 18 months: 38.3 ± 8.8 vs 33.6 ± 12.2 mg/day (P = 0.062)], especially in women receiving oral contraceptives. Reduction of testicular adrenal rest and adrenal size observed at 6 months remained stable. In one patient, an adrenal adenoma continually decreased over time. Subjective improvement in hirsutism was reported. Conclusions: Long-term use of CSHI is a safe and well-tolerated treatment option in a select set of adults with classic CAH. Improvements observed short term in disease control and subjective health status continued long term.",
keywords = "circadian, congenital adrenal hyperplasia, continuous subcutaneous hydrocortisone infusion",
author = "Ashwini Mallappa and Nella, {Aikaterini A.} and Ninet Sinaii and Hamsini Rao and Verena Gounden and Perritt, {Ashley F.} and Parag Kumar and Alexander Ling and Liu, {Chia Ying} and Soldin, {Steven J.} and Merke, {Deborah P.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/cen.13813",
language = "English (US)",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia

AU - Mallappa, Ashwini

AU - Nella, Aikaterini A.

AU - Sinaii, Ninet

AU - Rao, Hamsini

AU - Gounden, Verena

AU - Perritt, Ashley F.

AU - Kumar, Parag

AU - Ling, Alexander

AU - Liu, Chia Ying

AU - Soldin, Steven J.

AU - Merke, Deborah P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: In a phase 2 short-term (6 months) study of patients with congenital adrenal hyperplasia (CAH), continuous subcutaneous hydrocortisone infusion (CSHI) was found to be a safe, effective and well-tolerated method of replacing cortisol with improved disease and patient-related outcomes. Objective: To evaluate the safety and efficacy of long-term CSHI. Design: Single-centre, open-label, phase 2 extension study. Patients: Five adults with classic CAH. Measurements: Biomarkers of disease control, metabolic indices and health-related quality-of-life (HRQoL) estimates. Results: Six of eight patients chose to continue on long-term CSHI therapy. Compared to baseline, eighteen months of CSHI resulted in decreased (P = 0.043) 0700-hour ACTH, 17-hydroxyprogesterone, androstenedione and progesterone; increased whole-body lean mass (P = 0.024); and improved HRQoL, especially symptoms of adrenal insufficiency (P = 0.003). Findings at six and eighteen months did not differ, and improvements achieved in androgen control, lean body mass and HRQoL after 6 months of CSHI were maintained at eighteen months. The hydrocortisone dose appeared to decrease with time [6 vs 18 months: 38.3 ± 8.8 vs 33.6 ± 12.2 mg/day (P = 0.062)], especially in women receiving oral contraceptives. Reduction of testicular adrenal rest and adrenal size observed at 6 months remained stable. In one patient, an adrenal adenoma continually decreased over time. Subjective improvement in hirsutism was reported. Conclusions: Long-term use of CSHI is a safe and well-tolerated treatment option in a select set of adults with classic CAH. Improvements observed short term in disease control and subjective health status continued long term.

AB - Background: In a phase 2 short-term (6 months) study of patients with congenital adrenal hyperplasia (CAH), continuous subcutaneous hydrocortisone infusion (CSHI) was found to be a safe, effective and well-tolerated method of replacing cortisol with improved disease and patient-related outcomes. Objective: To evaluate the safety and efficacy of long-term CSHI. Design: Single-centre, open-label, phase 2 extension study. Patients: Five adults with classic CAH. Measurements: Biomarkers of disease control, metabolic indices and health-related quality-of-life (HRQoL) estimates. Results: Six of eight patients chose to continue on long-term CSHI therapy. Compared to baseline, eighteen months of CSHI resulted in decreased (P = 0.043) 0700-hour ACTH, 17-hydroxyprogesterone, androstenedione and progesterone; increased whole-body lean mass (P = 0.024); and improved HRQoL, especially symptoms of adrenal insufficiency (P = 0.003). Findings at six and eighteen months did not differ, and improvements achieved in androgen control, lean body mass and HRQoL after 6 months of CSHI were maintained at eighteen months. The hydrocortisone dose appeared to decrease with time [6 vs 18 months: 38.3 ± 8.8 vs 33.6 ± 12.2 mg/day (P = 0.062)], especially in women receiving oral contraceptives. Reduction of testicular adrenal rest and adrenal size observed at 6 months remained stable. In one patient, an adrenal adenoma continually decreased over time. Subjective improvement in hirsutism was reported. Conclusions: Long-term use of CSHI is a safe and well-tolerated treatment option in a select set of adults with classic CAH. Improvements observed short term in disease control and subjective health status continued long term.

KW - circadian

KW - congenital adrenal hyperplasia

KW - continuous subcutaneous hydrocortisone infusion

UR - http://www.scopus.com/inward/record.url?scp=85052479303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052479303&partnerID=8YFLogxK

U2 - 10.1111/cen.13813

DO - 10.1111/cen.13813

M3 - Article

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

ER -